Covaxin 50% Effective When Delta Was Dominant, Shows Lancet Study
NDTV
Study recently published in The Lancet showed that two doses of Covaxin, also known as BBV152, had 77.8 per cent efficacy against symptomatic disease and present no serious safety concerns.
Two doses of Covaxin are 50 per cent effective against symptomatic disease, according to the first real-world assessment of India's indigenous COVID-19 vaccine published in The Lancet Infectious Diseases journal.
Results of an interim study recently published in The Lancet showed that two doses of Covaxin, also known as BBV152, had 77.8 per cent efficacy against symptomatic disease and present no serious safety concerns.
The latest study assessed 2,714 hospital workers at the All India Institute of Medical Sciences (AIIMS) in Delhi, from April 15–May 15, who were symptomatic and underwent RT-PCR test for COVID-19 detection.
Researchers noted that the Delta variant was the dominant strain in India during the study period, accounting for approximately 80 per cent of all confirmed COVID-19 cases.
